Journal Article

A new member of the tripartite multidrug efflux pumps, MexVW–OprM, in Pseudomonas aeruginosa

Yang Li, Takehiko Mima, Yukiko Komori, Yuji Morita, Teruo Kuroda, Tohru Mizushima and Tomofusa Tsuchiya

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 52, issue 4, pages 572-575
Published in print October 2003 | ISSN: 0305-7453
Published online October 2003 | e-ISSN: 1460-2091 | DOI:
A new member of the tripartite multidrug efflux pumps, MexVW–OprM, in Pseudomonas aeruginosa

Show Summary Details


Objectives: Multidrug efflux pumps are thought to be involved in mediating multidrug resistance in Pseudomonas aeruginosa. Here we aim to characterize hitherto uncharacterized multidrug efflux pumps from P. aeruginosa.

Materials and methods: We isolated a mutant, YM442, which showed elevated resistance to several antimicrobial agents from P. aeruginosa YM44 lacking four major multidrug efflux pumps, MexAB, MexCD–OprJ, MexEF–OprN and MexXY. We cloned genes responsible for the resistance from chromosomal DNA of YM442 using YM44 as host.

Results: We designated the genes mexVW. Introduction of a recombinant plasmid pTAJ2 carrying the mexVW into YM44 cells conferred resistance to fluoroquinolones, tetracycline, chloramphenicol, erythromycin, ethidium bromide and acriflavine. Elevated ethidium bromide extrusion was observed with cells of YM442 and of YM44/pTAJ2. An outer membrane protein OprM was able to cooperate with MexVW. Elevated expression of the mexV gene was observed with YM442 compared with YM44.

Conclusions: MexV (membrane fusion protein)–MexW (RND-type membrane protein)–OprM is a tripartite multidrug efflux pump. It is suggested that other outer membrane component(s) could cooperate with MexVW.

Keywords: Keywords: MexVW, multidrug efflux pump, RND-type, P. aeruginosa

Journal Article.  2559 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.